Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterLetter

Autoantibody to PL-12 (Anti-Alanyl-tRNA Synthetase) in an African American Girl with Juvenile Dermatomyositis and Resolution of Interstitial Lung Disease

PATRICIA VEGA, MARIA IBARRA, ADRIENNE PRESTRIDGE and LAUREN M. PACHMAN
The Journal of Rheumatology February 2011, 38 (2) 394-395; DOI: https://doi.org/10.3899/jrheum.100608
PATRICIA VEGA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIA IBARRA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ADRIENNE PRESTRIDGE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LAUREN M. PACHMAN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pachman@northwestern.edu
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

Juvenile dermatomyositis (JDM) is an immune-mediated pediatric idiopathic inflammatory myopathy (IIM) characterized by muscle and skin inflammation1. Anti-PL-12 is a myositis-specific antibody (MSA), directed against alanine-tRNA synthetase2, often with debilitating interstitial lung disease (ILD), that is sporadically reported in childhood3. We describe a child with anti-PL-12 antibody who recovered lung function after therapy.

A 14-year-old African American girl developed bilateral ankle stiffness associated with swelling and redness of the upper eyelid. One month later, she noticed proximal weakness of shoulder girdle and pelvic girdle. Four months later, she had fever to 102°F; an erythematous rash over upper chest, arms, and upper eyelids; difficulty walking and getting up from bed, with shortness of breath during exertion. After admission to intensive care unit for suspected aspiration pneumonia, she was diagnosed with JDM on the basis of a muscle biopsy. She received intravenous (IV) steroid (30 mg/kg/dose) for 5 days, followed by oral prednisone (1 mg/kg/day), and was lost to followup.

Six months later, she was admitted to Children’s Memorial Hospital with fever, malaise, weakness, worsening rash, and bilateral knee arthritis. Laboratory data were elevated: creatine kinase 12,464 IU/l (normal 29–165 IU/l), aldolase 150 U/l (normal 3.4–8.6 U/l), alanine transaminase 156 IU/l (normal 2–30 IU/l), aspartate transaminase 257 IU/l (normal 16–52 IU/l), and lactate dehydrogenase 1496 IU/l (normal 126–289 IU/l). Markers of inflammation were increased: erythrocyte sedimentation rate (ESR) 37 mm/h (normal < 20 mm/h), C-reactive protein (CRP) 4.41 mg/dl (normal < 0.8 mg/dl), von Willebrand factor antigen (vWF:Ag) 420% (blood group B normal = 57%–241%); and elevated neopterin level 30.4 nm/l (normal < 10 nm/l). Periungual capillaroscopy showed dilated capillaries, and moderately severe dropout of the nailfold capillary end-row loop (ERL): 4.28 (normal value 7–10)4.

Tests for anti-dsDNA, Scl-70, and rheumatoid factor were negative, but her sera were positive for anti-Ro and anti-PL-12 (laboratory of Dr. I. Targoff5). On pulmonary function testing, she had decreased forced vital capacity, 73%, and diffusion capacity (DLCO/VA) of 66%, consistent with restrictive lung disease (Table 1). Computed tomography (CT) scan of the chest showed peripheral intralobular and interlobular septal thickening, early parenchymal cystic changes, and micronodules consistent with ILD (Figure 1). Dual energy X-ray absorptiometry scan showed a lumbar Z score of −1.9 (consistent with osteopenia) and vitamin D deficiency (25-hydroxy D total 25.2 ng/ml; normal 30–119 ng/ml]. Over the next 17 months, she developed persistent osteopenia (lumbar Z score of −2.6), despite supplementation with calcium and vitamin D and attaining a therapeutic level of vitamin D.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

CT scans before treatment showing peripheral intralobular interstitial thickening at the lung bases, left greater than right (A, B, C); and after treatment showing resolution of previous changes (D, E, F).

View this table:
  • View inline
  • View popup
Table 1.

Lung function data over time (dates shown). All data are percentages.

Therapy included 1 g IV methylprednisolone (IVMP), on 3 consecutive days, followed by twice weekly for the first 3 months; oral prednisolone 20 mg/day (0.43 mg/kg) on non-pulse days; methotrexate IV followed by subcutaneous (SC; 15 mg/m2) weekly and monthly IV cyclophosphamide (500 mg/m2) for 6 months. One month after completion of cyclophosphamide she had a normal leukocyte count, and she was given mycophenolate mofetil (MMF) 1000 mg daily (21 mg/kg/day) and continued with IVMP pulses every other week for 8 months and SC methotrexate weekly. IV administration of methylprednisolone was utilized because of prolonged active vasculitis characterized by a persistent rash associated with microvascular damage reflected by loss of nailfold capillary ERL, as well as positive indicators of immune activation and endothelial cell damage (elevated levels of vWF:Ag, low C4, decreased CD3-negative natural killer cells)6. Rouster-Stevens, et al showed that patients with JDM and ERL loss may have decreased bioavailability of oral prednisone compared with IVMP7. IVMP was tapered only after symptoms and all laboratory data were normal, including muscle enzymes and other markers of inflammation (ESR, CRP, and vWF:Ag), following the authors’ treatment protocol for severe JDM8. Two years after starting therapy at Children’s Memorial Hospital, she takes prednisone 5 mg daily (0.1 mg/kg/day); SC methotrexate 15 mg/m2 every week; MMF 2500 mg daily (40 mg/kg/daily); folic acid 1 mg; calcium 1600 mg; and vitamin D 50,000 units/month. The pulmonary function essentially normalized after 5 months of therapy and the serologic indices of inflammation normalized after 17 months. Her CT scan showed resolution of interstitial and interlobular septal thickening with minimal residual micronodules (Figure 1).

The most common myositis-specific antibodies are directed against aminoacyl-tRNA synthetase, one of the enzymes catalyzing the attachment of a particular amino acid to its transfer RNA2. Patients with aminoacyltRNA synthetase have the anti-synthetase syndrome: myositis, polyarthritis, fever, Raynaud’s phenomenon, ILD, and mechanic’s hands9. In a study of 77 children, 12 (16%) had myositis-specific antibodies and one had anti-PL-123. Myositis-specific antibodies are found in 16%–26% of adults with IIM2; anti-PL-12 is present in < 5%. Anti-PL-12 is highly associated with ILD5; in 31 adults, ILD was present in 90%, and preceded the diagnosis of connective tissue disease in 53%10.

Our patient’s pulmonary function tests showed a pattern of restrictive lung disease, commonly associated with diminished core strength as well as a diffusion defect11. The chest CT identified interlobular septal thickening, one of the most common radiological findings in PL-12-positive adults. Although myositis is usually mild in patients with anti-PL-125,10, our patient had severe myositis with markedly elevated muscle enzymes, and her score on the Childhood Myositis Assessment Scale12 was markedly decreased at 21/52. She was negative for antibody to ribonuclear protein, which is present in 36%–65% of patients who are anti-PL-12-positive10. VWF:Ag is often an indicator of a disease flare in IIM13,14, and our patient exhibited high vWF:Ag levels at presentation, persisting for 9 months. Her disease course was similar to those of adults with both anti-PL-12 and anti-Ro antibody, in whom ILD is difficult to control. In contrast to reported cases, however, her pulmonary function tests normalized and the chest CT scan showed significant resolution of ILD. To our knowledge this is the first complete report of a child with IIM with both anti-PL-12 and anti-Ro autoantibodies and improvement of lung function in response to intensive immunosuppressive therapy.

Footnotes

  • Supported by NIH/NIAMS R01 AR48289, the Cure JM Foundation, and the Macy’s Miracle Foundation.

REFERENCES

  1. 1.↵
    1. Feldman BM,
    2. Rider LG,
    3. Reed AM,
    4. Pachman LM
    . Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008;371:2201–12.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Hengstman GJ,
    2. van Engelen BG,
    3. Vree Egberts WT,
    4. van Venrooij WJ
    . Myositis-specific autoantibodies: Overview and recent developments. Curr Opin Rheumatol 2001;13:476–82.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Rider LG,
    2. Miller FW,
    3. Targoff IN,
    4. Sherry DD,
    5. Samayoa E,
    6. Lindahl M,
    7. et al.
    A broadened spectrum of juvenile myositis-specific autoantibodies in children. Arthritis Rheum 1994;37:1534–8.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Christen-Zaechs S,
    2. Seshadri R.,
    3. Sundberg J,
    4. Paller AS,
    5. Pachman LM
    . Juvenile dermatomyositis: Persistent association of nailfold capillaroscopy changes and skin involvement over 36 months with duration of untreated disease. Arthritis Rheum 2008;58:571–6.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Targoff IN,
    2. Arnett FC
    . Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med 1990;88:241–51.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Pachman LM,
    2. Geraci N,
    3. Morgan G,
    4. Daniels B,
    5. Seshadri R,
    6. Sullivan D,
    7. et al.
    Absolute number of circulating CD3-CD56+/CD16+ natural killer (NK) cells, a potential biomarker of disease activity in juvenile dermatomyositis (JDM) [abstract]. Arthritis Rheum 2008;58 Suppl:S225.
    OpenUrl
  7. 7.↵
    1. Rouster-Stevens KA,
    2. Gursahaney A,
    3. Ngai K-L,
    4. Daru JA,
    5. Pachman LM
    . Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Care Res 2008;59:222–66.
    OpenUrlCrossRef
  8. 8.↵
    1. Rouster-Stevens KA,
    2. Morgan GA,
    3. Wang D,
    4. Pachman LM
    . Mycophenolate mofetil, a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res 2010;62:1446–51.
    OpenUrlCrossRef
  9. 9.↵
    1. Love LA,
    2. Leff RL,
    3. Fraser DD,
    4. Targoff IN,
    5. Dalakas M,
    6. Plotz PH,
    7. et al.
    A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360–74.
    OpenUrlPubMed
  10. 10.↵
    1. Kalluri M,
    2. Sahn SA,
    3. Oddis CV,
    4. Gharib SL,
    5. Christopher-Stine L,
    6. Danoff SK,
    7. et al.
    Clinical profile of anti-PL-12 autoantibody: Cohort study and review of the literature. Chest 2009;135:1550–6.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Pachman LM,
    2. Cooke N
    . Juvenile dermatomyositis: A clinical and immunological study. J Pediatr 1980;96:226–34.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Huber AM,
    2. Feldman BM,
    3. Rennebohm RM,
    4. Hicks JE,
    5. Lindsley CB,
    6. Perez MD,
    7. et al.
    Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004;50:1595–603.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Guzman J,
    2. Petty RE,
    3. Malleson PN
    . Monitoring disease activity in juvenile dermatomyositis: The role of von Willebrand factor and muscle enzymes. J Rheumatol 1994;21:739–43.
    OpenUrlPubMed
  14. 14.↵
    1. Ansell BA,
    2. Miller JJ III.,
    3. Pachman LM,
    4. Sullivan DB
    . Controversies in juvenile dermatomyositis. J Rheumatol 1990;17:1–6.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 38, Issue 2
1 Feb 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Autoantibody to PL-12 (Anti-Alanyl-tRNA Synthetase) in an African American Girl with Juvenile Dermatomyositis and Resolution of Interstitial Lung Disease
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Autoantibody to PL-12 (Anti-Alanyl-tRNA Synthetase) in an African American Girl with Juvenile Dermatomyositis and Resolution of Interstitial Lung Disease
PATRICIA VEGA, MARIA IBARRA, ADRIENNE PRESTRIDGE, LAUREN M. PACHMAN
The Journal of Rheumatology Feb 2011, 38 (2) 394-395; DOI: 10.3899/jrheum.100608

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Autoantibody to PL-12 (Anti-Alanyl-tRNA Synthetase) in an African American Girl with Juvenile Dermatomyositis and Resolution of Interstitial Lung Disease
PATRICIA VEGA, MARIA IBARRA, ADRIENNE PRESTRIDGE, LAUREN M. PACHMAN
The Journal of Rheumatology Feb 2011, 38 (2) 394-395; DOI: 10.3899/jrheum.100608
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Does the BNT162b2 Vaccine Trigger Antimelanoma Differentiation-Associated Gene 5 Antibody–Positive Interstitial Lung Disease?
  • Duration of Steroid Therapy and Temporal Artery Biopsy Positivity in Giant Cell Arteritis: A Retrospective Cohort Study
  • Desk Rejections: Not Without Due Deliberation
Show more Letters

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire